Tarsus Pharmaceuticals (TARS) Gross Margin (2021 - 2026)

Tarsus Pharmaceuticals' Gross Margin history runs 6 years deep, the most recent figure standing at 94.2% for Q1 2026.

• In Q1 2026, Gross Margin rose 85.0% year-over-year to 94.2%; the TTM figure through Mar 2026 stood at 93.48% (up 49.0% YoY), while the FY2025 annual figure was 93.2%, up 21.0% from the prior year.
• Gross Margin was 94.2% for Q1 2026 at Tarsus Pharmaceuticals, up from 92.8% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 105.55% in Q4 2022 to a low of 79.85% in Q3 2023.
• Historically, Gross Margin has averaged 93.76% across 5 years, with a median of 93.35% in 2025.
• The sharpest annual moves came in 2023 and 2024: Gross Margin slumped 1485 bps in 2023, then soared 1341 bps in 2024.
• A 5-year view of Gross Margin shows it stood at 105.55% in 2022, then retreated by 14 bps to 90.7% in 2023, then rose by 2 bps to 92.58% in 2024, then advanced by 0 bps to 92.8% in 2025, then advanced by 2 bps to 94.2% in 2026.
• The last three Gross Margin figures came in at 94.2% (Q1 2026), 92.8% (Q4 2025), and 93.0% (Q3 2025), per Business Quant data.